| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Neurokinin A TFA targets the NK-2 (Neurokinin 2) receptor. It is an endogenous ligand and agonist for this receptor. It plays a significant role as a key mediator in human gastrointestinal and airway tissues. It is involved in the regulation of the nervous system, inflammation, and pain.
|
|---|---|
| ln Vitro |
Within the tachykinin family of peptide neurotransmitters, neurokinin A (substance K) has the potential to play a significant role as a key mediator in human gastrointestinal and airway tissues. Through the NK-2 receptor, which is thought to be found on smooth muscle cells and pharmacologically linked to a GTP-binding protein, neurokinin A exerts its action. Tachykinins are a family of peptide neurotransmitters that includes neurokinin A. These peptides have a broad tissue distribution and are connected to both the peripheral and central nervous systems. Substance P and Neurokinin A or Substance K are the most well-known members of the chykinin family, which is characterized by the same COOH-terminal structure of Phe-X-Gly-Leu-Met-NH[1].
In vitro, Neurokinin A TFA is a peptide neurotransmitter of the tachykinin family. All tachykinins have a conserved COOH-terminal structure Phe-X-Gly-Leu-Met-NH2. It acts through the NK-2 receptor localized on smooth muscle cells and is pharmacologically coupled to GTP-binding proteins. It is associated with the central and peripheral nervous systems and exhibits a wide tissue distribution. |
| ln Vivo |
In vivo, Neurokinin A acts as a major mediator in human airway and gastrointestinal tissues. It regulates the nervous system, inflammation, and pain. It is used in research on asthma, inflammatory bowel disease, rheumatoid arthritis pain, and psychiatric disorders. However, comprehensive in vivo efficacy data from published literature are limited.
|
| Enzyme Assay |
For non-cell-based receptor binding assays, Neurokinin A TFA can be evaluated using membrane preparations from cells expressing human NK-2 receptors. Radioligand binding displacement experiments are performed using a suitable radiolabeled ligand such as [125I]-Neurokinin A. Membrane homogenates are incubated with increasing concentrations of the test compound and a fixed concentration of the radioligand. Bound radioligand is separated from free by rapid filtration through glass fiber filters. Non-specific binding is determined in the presence of excess unlabeled Neurokinin A. Ki values are calculated from displacement curves using nonlinear regression analysis.
|
| Cell Assay |
For in vitro cellular assays, cells expressing human NK-2 receptors are cultured in appropriate media. For functional assays, calcium mobilization or cAMP accumulation is measured. Cells are treated with various concentrations of Neurokinin A TFA, and the signaling response is measured using fluorescent indicators or ELISA-based detection. EC50 values are calculated from dose-response curves. The compound's ability to activate NK-2 receptor-mediated signaling is assessed.
|
| Animal Protocol |
For in vivo animal studies, Neurokinin A TFA can be administered to rodents via appropriate routes. In models of asthma, its effects on airway inflammation and hyperresponsiveness are assessed. In models of inflammatory bowel disease, its effects on intestinal inflammation are evaluated. In models of pain, its effects on nociceptive responses are assessed. Dosing regimens vary depending on the specific model and desired exposure levels.
|
| ADME/Pharmacokinetics |
Neurokinin A TFA has a molecular weight of 1247.34 and a molecular formula of C52H81F3N14O16S. It has a purity of 98.70%. The compound should be stored at -20°C or below. It is soluble in appropriate solvents for research use. It is for research use only and is not intended for human consumption.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Neurokinin A TFA has not been extensively reported. As a peptide neurotransmitter, potential adverse effects may include modulation of neurokinin signaling. The compound is for research use only and is not intended for human consumption. Standard safety precautions should be observed when handling the compound.
|
| References | |
| Additional Infomation |
Neurokinin A TFA (Substance K TFA, CAS 2828433-19-6) is a peptide neurotransmitter of the tachykinin family that acts via the NK-2 receptor. It is an endogenous ligand and agonist for the NK-2 receptor, regulating the nervous system, inflammation, and pain. It is used in research on asthma, inflammatory bowel disease, rheumatoid arthritis pain, and psychiatric disorders. It is available for research purposes only.
|
| Molecular Formula |
C52H81F3N14O16S
|
|---|---|
| Molecular Weight |
1247.34
|
| Exact Mass |
1246.562
|
| CAS # |
2828433-19-6
|
| Related CAS # |
Neurokinin A;86933-74-6
|
| PubChem CID |
137700150
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
17
|
| Hydrogen Bond Acceptor Count |
23
|
| Rotatable Bond Count |
37
|
| Heavy Atom Count |
86
|
| Complexity |
2120
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
C(F)(F)(F)C(=O)O.[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@]([H])([C@H](O)C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC1N=CNC=1)(C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N)CCSC)CC1C=CC=CC=1
|
| InChi Key |
CPQMHLIZWAQHOV-LEUAYMAXSA-N
|
| InChi Code |
InChI=1S/C50H80N14O14S.C2HF3O2/c1-26(2)18-34(45(73)58-32(42(53)70)15-17-79-6)57-38(67)23-55-49(77)40(27(3)4)63-47(75)35(19-29-12-8-7-9-13-29)60-48(76)37(24-65)62-46(74)36(21-39(68)69)61-50(78)41(28(5)66)64-44(72)33(14-10-11-16-51)59-43(71)31(52)20-30-22-54-25-56-30;3-2(4,5)1(6)7/h7-9,12-13,22,25-28,31-37,40-41,65-66H,10-11,14-21,23-24,51-52H2,1-6H3,(H2,53,70)(H,54,56)(H,55,77)(H,57,67)(H,58,73)(H,59,71)(H,60,76)(H,61,78)(H,62,74)(H,63,75)(H,64,72)(H,68,69);(H,6,7)/t28-,31+,32+,33+,34+,35+,36+,37+,40+,41+;/m1./s1
|
| Chemical Name |
(3S)-3-[[(2S,3R)-2-[[(2S)-6-amino-2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]hexanoyl]amino]-3-hydroxybutanoyl]amino]-4-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-oxobutanoic acid;2,2,2-trifluoroacetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (80.17 mM)
H2O: 50 mg/mL (40.09 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (2.00 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (2.00 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (2.00 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 25 mg/mL (20.04 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.8017 mL | 4.0085 mL | 8.0171 mL | |
| 5 mM | 0.1603 mL | 0.8017 mL | 1.6034 mL | |
| 10 mM | 0.0802 mL | 0.4009 mL | 0.8017 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
